Kyri van Hoose
Net worth: 299 877 $ as of 31/08/2026
Net worth: 299 877 $ as of 31/08/2026
Kyri K.
van Hoose is Vice President-Accounting at Turning Point Therapeutics, Inc. since 2021.
Mr. van Hoose is Chief Financial Officer & Senior Vice President at Dermata Therapeutics, Inc. since 2021.
Former roles include Corporate Controller & Senior Director-Finance at ACADIA Pharmaceuticals, Inc. from 2005 to 2016, Head-Finance at Avelas Biosciences, Inc. from 2017 to 2019, Head-Finance at Curzion Pharmaceuticals, Inc. from 2019 to 2020, and Chief Financial Officer at TEGA Therapeutics, Inc. from 2020 to 2021.
Education includes an undergraduate degree from the University of Southern California in 2000 and an MBA from the University of California, Irvine in 2005.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 16/08/2026 | 232,463 ( 8.2% ) | 299 877 $ | 31/08/2026 |
| Companies | Position | Start |
|---|---|---|
| TURG POIN | Comptroller/Controller/Auditor | 05/05/2021 |
| DERMATA THERAPEUTICS, INC. | Director of Finance/CFO | 01/09/2021 |
| Companies | Position | End |
|---|---|---|
TEGA Therapeutics, Inc.
TEGA Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics | Director of Finance/CFO | 30/04/2021 |
Curzion Pharmaceuticals, Inc.
Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Corporate Officer/Principal | 01/04/2020 |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Develops integrated suite of therapeutic and imaging agents for treatment of cancer | Director of Finance/CFO | 01/07/2019 |
| ACADIA PHARMACEUTICALS INC. | Comptroller/Controller/Auditor | 01/02/2016 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 8 |
|---|---|
ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage structure based drug design company for cancer diseases | Health Technology |
Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which focusing on the treatment of medical and aesthetic skin conditions | Health Technology |
University of Southern California
University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Develops integrated suite of therapeutic and imaging agents for treatment of cancer | Health Services |
Curzion Pharmaceuticals, Inc.
Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
TEGA Therapeutics, Inc.
TEGA Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics | Health Technology |
Select your edition
All financial news and data tailored to specific country editions